Robotic surgery using Senhance^® robotic platform: single center experience with first 100 cases

Area of Science:

• Minimally Invasive Surgery
• Surgical Robotics
• Surgical Technology Evaluation

Background:

• The da Vinci system has dominated robotic surgery perceptions.
• Limited published data exists on alternative robotic platforms like the Senhance system.
• The Senhance system offers a novel approach to robotic-assisted procedures.

Purpose of the Study:

• To prospectively analyze the initial 100 robotic surgeries using the Senhance system.
• To evaluate the feasibility and safety of the Senhance system across multiple surgical specialties.
• To assess outcomes including operative time, complications, and hospital stay.

Main Methods:

• Prospective analysis of 100 consecutive robotic surgeries.
• Procedures included abdominal surgery, gynecology, and urology.
• Data collected on patient demographics, surgical type, duration, outcomes, and complications.

Main Results:

• 49% of patients had malignant diseases, including prostate, renal, endometrial, ovarian, and colorectal cancers.
• Average operative time was 2 hours 25 minutes, with an average hospital stay of 4 days.
• Low conversion rate (3%) and complication rate (6%), with no mortality.

Conclusions:

• The Senhance robotic system is feasible and safe for general surgery, gynecology, and urology.
• The system demonstrates promising outcomes in a diverse patient population.
• Wider global adoption of the Senhance system is anticipated.